HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Debuts List For Rapidly Announcing Noncompliant Ingredients In Supplements

Executive Summary

FDA announces addition of Dietary Supplement Ingredient Advisory List page to its website to identify ingredients it has preliminary determined should be used in dietary supplements. It also publishes warning letters submitted recently to firms marketing supplements containing two ingredients agency has concluded should not be used: eight were warned about using an ingredient identified as "DMHA" and three about using phenibut.

You may also be interested in...



FDA's Latest Hornedine Find Is On Texas Firm’s Supplement Labels During Website Inspection

Hornedine isn’t an “old” dietary ingredient exempt from pre-market notification with proof its safety because it wasn’t available in the US food supply before October 1994. "T

US Supplement Firm Warned About Phenibut After Failing To Pull PTSD, Detox, Anxiety Claims

Latest FDA warning to Chill6 doesn’t reference previous letter but lists larger number of violations along with more details about the problems. Agency also recently added salt scrub therapies to its list of products as marketed with fraudulent coronavirus treatment claims.

Another Notice For Comments On Kratom: Cue Second Wave Of Support For Botanical In US?

FDA states in Federal Register notice that WHO has requested information on whether kratom – mitragynine, 7-hydroxymitragynine – should be added to the United Nations’ schedule of controlled substances.

Related Content

Topics

UsernamePublicRestriction

Register

RS148731

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel